GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab A/S (STU:GE91) » Definitions » 6-Month Price Index

Genmab A/S (STU:GE91) 6-Month Price Index : 0.92 (As of May. 28, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Genmab A/S 6-Month Price Index?

6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. It’s calculated by current share price divided by share price 6-months ago. As of today (2024-05-28), Genmab A/S's 6-Month Price Index is 0.92.

Competitive Comparison of Genmab A/S's 6-Month Price Index

For the Biotechnology subindustry, Genmab A/S's 6-Month Price Index, along with its competitors' market caps and 6-Month Price Index data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genmab A/S  (STU:GE91) 6-Month Price Index Calculation

6-Month Price Index is calculated as following:

6-Month Price Index=Current Share Price / Share Price 6-Months Ago

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genmab A/S  (STU:GE91) 6-Month Price Index Explanation

Price Index (PI) also called momentum. Strategies involving Price Index are also known as momentum strategies as they allow investors to profit from a company’s stock price. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago.

The investment strategy for momentum investors is to buy winners and sell losers. That is, buy stocks that performed well and sell stocks that performed poorly in the past.

Genmab A/S 6-Month Price Index Related Terms

Thank you for viewing the detailed overview of Genmab A/S's 6-Month Price Index provided by GuruFocus.com. Please click on the following links to see related term pages.

Genmab A/S (STU:GE91) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab A/S (STU:GE91) » Definitions » 6-Month Price Index
Comparable Companies
OCSE:ZEAL OCSE:ALK B OCSE:BAVA OCSE:GUBRA OCSE:PEG OCSE:NOVO B VRTX REGN ASX:CSL XKRX:207940 MRNA XKRX:068270 XBRU:ARGX XBRU:UCB BNTX ALNY BGNE BMRN SZSE:300122 RPRX
Traded in Other Exchanges
GNMSF:USA GMAB:USA GMAB:Mexico GMABc:UK 0MGB:UK GMAB:Denmark GE91:Germany
Address
Kalvebod Brygge 43, Copenhagen, DNK, 1560
Website
https://www.genmab.com
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab is also the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), and Tivdak (partnered with Seagen) for cervical cancer. Genmab has several pipeline candidates targeting other oncologic indications.

Genmab A/S (STU:GE91) Headlines

No Headlines